Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362231427> ?p ?o ?g. }
- W4362231427 endingPage "1152" @default.
- W4362231427 startingPage "1148" @default.
- W4362231427 abstract "No AccessJournal of UrologyClinical Urology: Original Articles1 Apr 1999LONG-TERM RESULTS FOLLOWING ADJUVANT CHEMOTHERAPY IN PATIENTS WITH CLINICAL STAGE I TESTICULAR NONSEMINOMATOUS MALIGNANT GERM CELL TUMORS WITH HIGH RISK FACTORS DOMINIK BOHLEN, MARKUS BORNER, ROLAND W. SONNTAG, MARTIN F. FEY, and URS E. STUDER DOMINIK BOHLENDOMINIK BOHLEN More articles by this author , MARKUS BORNERMARKUS BORNER More articles by this author , ROLAND W. SONNTAGROLAND W. SONNTAG More articles by this author , MARTIN F. FEYMARTIN F. FEY More articles by this author , and URS E. STUDERURS E. STUDER More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)61615-XAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We determine the efficacy and safety of 2 cycles of adjuvant chemotherapy after orchiectomy in patients with high risk clinical stage I nonseminomatous germ cell tumor of the testis as an alternative to retroperitoneal lymphadenectomy or watchful waiting. Materials and Methods: A total of 60 consecutive patients with clinical stage I nonseminomatous germ cell tumor of the testis and 1 or more risk factors were entered into this prospective study. Criteria for high risk were embryonal cell carcinoma, tumor invasion of blood or lymph vessels, or tumor stage pT2 or greater. Chemotherapy consisted of 2 cycles of cisplatin, vinblastine and bleomycin or bleomycin, etoposide and cisplatin. Results: Of the 60 patients 1 refused chemotherapy and 1 was lost to followup 1.5 years after treatment. The remaining 58 patients have been followed for a median of 93 months (range 32 to 146). World Health Organization grade 4 toxicity was observed in 9 of the 116 chemotherapy cycles, and consisted mainly of transient neutropenia and thrombocytopenia. No significant long-term sequelae were detected. There was 1 relapse after 22 months in a patient with adult teratoma in the ipsilateral region of the iliac vessels who remained disease-free 85 months after surgical excision of the lesion. Another patient had a seminoma in the contralateral testicle with interaortocaval lymph node metastases 7.5 years after adjuvant chemotherapy. The remaining 56 men are without relapse or contralateral tumor to date. Conclusions: We recommend adjuvant chemotherapy as an efficient therapeutic alternative to retroperitoneal lymphadenectomy for high risk nonseminomatous germ cell tumor of the testis. References 1 : Treatment of intratubular germ-cell neoplasia and low-stage testicular cancer. Curr. Opin. Urol.1995; 5: 255. Google Scholar 2 : Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965 to 1989): modifications of technique and impact on ejaculation. J. Urol.1993; 149: 237. Link, Google Scholar 3 : Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchidectomy alone. Lancet1987; 2: 294. Crossref, Medline, Google Scholar 4 : A surveillance study of clinical stage I nonseminomatous germ cell tumors of the testis: 10-year followup. J. Urol.1995; 154: 1045. Link, Google Scholar 5 : Medical research council prospective study of surveillance for stage I testicular teratoma. J. Clin. Oncol.1992; 10: 1762. Crossref, Medline, Google Scholar 6 : Surgical treatment of stage-I non-seminomatous germ cell testis tumor. Eur. Urol.1990; 17: 97. Google Scholar 7 : Surveillance after orchidectomy for patients with clinical stage I nonseminomatous testis tumors. J. Clin. Oncol.1992; 10: 564. Google Scholar 8 : Prognostic factors in nonseminomatous testicular cancer. J. Urol.1986; 135: 497. Link, Google Scholar 9 : Prognostic factors in stage I non-seminomatous germ cell testicular tumors managed by orchiectomy and surveillance: implications for adjuvant chemotherapy. J. Clin. Oncol.1986; 4: 1031. Google Scholar 10 : Konnen Risikofaktoren die Strategien in Stadium I des Nicht-Seminoms bestimmen?. Akt. Urol.1995; 26: 79. Google Scholar 11 : Staging relationships and outcome in early stage testicular cancer: a report from the testicular cancer intergroup study. J. Urol.1991; 145: 1178. Link, Google Scholar 12 : Pathology of germ cell tumors of testis. A progress report. Cancer1980; 45: 1735. Google Scholar 13 : Testis. In: . New York: Springer Verlag1992: 251. Google Scholar 14 : Low toxicity with continuous infusion of high dose bleomycin in poor prognostic testicular cancer. Amer. J. Clin. Oncol.1993; 16: 323. Google Scholar 15 : Adjuvant chemotherapy after orchiectomy in high-risk patients with clinical stage I non-seminomatous testicular cancer. Eur. Urol.1993; 23: 444. Google Scholar 16 : Treatment of clinical stage I testicular cancer and a possible role for new biological prognostic parameters. J. Cancer Res. Clin. Oncol.1996; 122: 575. Google Scholar 17 : Retroperitoneal imaging with third and fourth generation computed axial tomography in clinical stage I nonseminomatous germ cell tumors. Urology1994; 44: 548. Google Scholar 18 : Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. New Engl. J. Med.1987; 317: 1433. Google Scholar 19 : Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a southeastern cancer study group protocol. J. Clin. Oncol.1989; 7: 387. Google Scholar 20 : Complications of primary retroperitoneal lymph node dissection. J. Urol.1994; 152: 424. Link, Google Scholar 21 : Results of adjuvant chemotherapy for low-stage nonseminomatous germ cell tumors of the testis with vascular invasion. Cancer1988; 62: 1471. Google Scholar 22 : Adjuvant chemotherapy in patients with high-risk stage I non seminomatous germ cell tumors. J. Urol.1992; 147: 335A. abstract 492. Google Scholar 23 : Percentage of embryonal carcinoma and of vascular invasion predicts pathological stage in clinical stage I non-seminomatous testicular cancer. Cancer Res.1994; 54: 362. Google Scholar 24 : Pilot study to evaluate impact of a policy of adjuvant chemotherapy for high risk stage 1 malignant teratoma on overall relapse rate of stage 1 cancer patients. J. Urol.1992; 148: 1453. Abstract, Google Scholar 25 : Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. J. Clin. Oncol.1996; 14: 441. Google Scholar 26 : Short course adjuvant chemotherapy in high risk stage I nonseminomatous germ-cell tumors of the testis: a medical research council report. J. Clin. Oncol.1996; 14: 1106. Google Scholar 27 : Bleomycin in germ cell tumor therapy: not all regimens are created equal. J. Clin. Oncol.1997; 15: 1717. Google Scholar 28 : Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J. Clin. Oncol.1991; 9: 1163. Google Scholar 29 : Treatment of testicular cancer and the development of secondary malignancies. J. Clin. Oncol.1995; 13: 283. Google Scholar 30 : Bilateral germ cell testicular tumors in New Zealand: experience in Auckland and Christchurch 1978–1994. J. Clin. Oncol.1996; 14: 2061. Google Scholar 31 : Fertility issues in the therapy of nonseminomatous testicular tumors. Urol. Clin. N. Amer.1987; 14: 731. Google Scholar 32 : Long-term morbidity and quality of life in testicular cancer patients. Scand. J. Urol. Nephrol.1991; 138: 241. Google Scholar 33 : Long-term fertility and leydig cell function in patients treated for germ cell cancer with cisplatin, vinblastine and bleomycin versus surveillance. J. Clin. Oncol.1990; 8: 1695. Google Scholar 34 : Fertility after chemotherapy for testicular germ cell cancers. J. Clin. Oncol.1997; 15: 239. Google Scholar 35 : Adjuvant chemotherapy in high risk stage I non-seminomatous germ cell tumors. Proc. American Society of Clinical Oncology1997; 16: 320a. Google Scholar 36 : Adjuvant chemotherapy for stage I non-seminomatous testicular cancer. S. Afr. Med. J.1994; 84: 605. Google Scholar 37 : The value of prognostic factors in the management of stage I nonseminomatous germ cell testicular tumors. Neoplasma1996; 43: 195. Google Scholar From the Department of Urology and Institute of Medical Oncology, University of Berne, Berne, Switzerland© 1999 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byWilliams S, Kacker R, Winston D, Bahnson E, Steele G and Richie J (2011) Predictors of Positive Retroperitoneal Lymph Nodes in Patients With High Risk Testicular CancerJournal of Urology, VOL. 186, NO. 6, (2245-2248), Online publication date: 1-Dec-2011.Williams S, McDermott D, Dock W, Bahnson E, Berry A, Steele G and Richie J (2009) Retroperitoneal Lymph Node Dissection in Patients With High Risk Testicular CancerJournal of Urology, VOL. 181, NO. 5, (2097-2102), Online publication date: 1-May-2009.Westermann D, Schefer H, Thalmann G, Karamitopoulou-Diamantis E, Fey M and Studer U (2007) Long-Term Followup Results of 1 Cycle of Adjuvant Bleomycin, Etoposide and Cisplatin Chemotherapy for High Risk Clinical Stage I Nonseminomatous Germ Cell Tumors of the TestisJournal of Urology, VOL. 179, NO. 1, (163-166), Online publication date: 1-Jan-2008.STEPHENSON A, BOSL G, BAJORIN D, STASI J, MOTZER R and SHEINFELD J (2018) RETROPERITONEAL LYMPH NODE DISSECTION IN PATIENTS WITH LOW STAGE TESTICULAR CANCER WITH EMBRYONAL CARCINOMA PREDOMINANCE AND/OR LYMPHOVASCULAR INVASIONJournal of Urology, VOL. 174, NO. 2, (557-560), Online publication date: 1-Aug-2005.Chang S, Smith J, Girasole C, Baumgartner R, Roth B and Cookson M (2018) Beneficial Impact of a Clinical Care Pathway in Patients with Testicular Cancer Undergoing Retroperitoneal Lymph Node DissectionJournal of Urology, VOL. 168, NO. 1, (87-92), Online publication date: 1-Jul-2002.ROELEVELD T, HORENBLAS S, MEINHARDT W, van de VIJVER M, KOOI M and HUININK W (2018) SURVEILLANCE CAN BE THE STANDARD OF CARE FOR STAGE I NONSEMINOMATOUS TESTICULAR TUMORS AND EVEN HIGH RISK PATIENTSJournal of Urology, VOL. 166, NO. 6, (2166-2170), Online publication date: 1-Dec-2001.BÖHLEN D, BURKHARD F, MILLS R, SONNTAG R and STUDER U (2018) FERTILITY AND SEXUAL FUNCTION FOLLOWING ORCHIECTOMY AND 2 CYCLES OF CHEMOTHERAPY FOR STAGE I HIGH RISK NONSEMINOMATOUS GERM CELL CANCERJournal of Urology, VOL. 165, NO. 2, (441-444), Online publication date: 1-Feb-2001.JANETSCHEK G, HOBISCH A, PESCHEL R, HITTMAIR A and BARTSCH G (2018) LAPAROSCOPIC RETROPERITONEAL LYMPH NODE DISSECTION FOR CLINICAL STAGE I NONSEMINOMATOUS TESTICULAR CARCINOMA: LONG-TERM OUTCOMEJournal of Urology, VOL. 163, NO. 6, (1793-1796), Online publication date: 1-Jun-2000.FOSTER R and DONOHUE J (2018) RETROPERITONEAL LYMPH NODE DISSECTION FOR THE MANAGEMENT OF CLINICAL STAGE I NONSEMINOMAJournal of Urology, VOL. 163, NO. 6, (1788-1792), Online publication date: 1-Jun-2000.STUDER U, BURKHARD F and SONNTAG R (2018) RISK ADAPTED MANAGEMENT WITH ADJUVANT CHEMOTHERAPY IN PATIENTS WITH HIGH RISK CLINICAL STAGE I NONSEMINOMATOUS GERM CELL TUMORJournal of Urology, VOL. 163, NO. 6, (1785-1787), Online publication date: 1-Jun-2000. Volume 161Issue 4April 1999Page: 1148-1152 Advertisement Copyright & Permissions© 1999 by American Urological Association, Inc.MetricsAuthor Information DOMINIK BOHLEN More articles by this author MARKUS BORNER More articles by this author ROLAND W. SONNTAG More articles by this author MARTIN F. FEY More articles by this author URS E. STUDER More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
- W4362231427 created "2023-04-05" @default.
- W4362231427 creator A5000513493 @default.
- W4362231427 creator A5008912538 @default.
- W4362231427 creator A5047279072 @default.
- W4362231427 creator A5070498394 @default.
- W4362231427 creator A5075222976 @default.
- W4362231427 date "1999-04-01" @default.
- W4362231427 modified "2023-10-18" @default.
- W4362231427 title "LONG-TERM RESULTS FOLLOWING ADJUVANT CHEMOTHERAPY IN PATIENTS WITH CLINICAL STAGE I TESTICULAR NONSEMINOMATOUS MALIGNANT GERM CELL TUMORS WITH HIGH RISK FACTORS" @default.
- W4362231427 cites W1584634571 @default.
- W4362231427 cites W180392997 @default.
- W4362231427 cites W1864159082 @default.
- W4362231427 cites W1866911875 @default.
- W4362231427 cites W1902616231 @default.
- W4362231427 cites W1905164065 @default.
- W4362231427 cites W1935504810 @default.
- W4362231427 cites W1941136858 @default.
- W4362231427 cites W1956443396 @default.
- W4362231427 cites W1961050161 @default.
- W4362231427 cites W1986119125 @default.
- W4362231427 cites W1991220457 @default.
- W4362231427 cites W1996346613 @default.
- W4362231427 cites W1998375776 @default.
- W4362231427 cites W2008984621 @default.
- W4362231427 cites W2046961328 @default.
- W4362231427 cites W2078244534 @default.
- W4362231427 cites W2083870227 @default.
- W4362231427 cites W2108522817 @default.
- W4362231427 cites W2220613250 @default.
- W4362231427 cites W2224031282 @default.
- W4362231427 cites W2302172452 @default.
- W4362231427 cites W2340182039 @default.
- W4362231427 cites W2412318009 @default.
- W4362231427 cites W2417380146 @default.
- W4362231427 cites W2464545349 @default.
- W4362231427 cites W2467424047 @default.
- W4362231427 cites W4319054742 @default.
- W4362231427 cites W4375269684 @default.
- W4362231427 cites W2752971847 @default.
- W4362231427 doi "https://doi.org/10.1016/s0022-5347(01)61615-x" @default.
- W4362231427 hasPublicationYear "1999" @default.
- W4362231427 type Work @default.
- W4362231427 citedByCount "75" @default.
- W4362231427 countsByYear W43622314272013 @default.
- W4362231427 countsByYear W43622314272014 @default.
- W4362231427 countsByYear W43622314272015 @default.
- W4362231427 countsByYear W43622314272016 @default.
- W4362231427 countsByYear W43622314272018 @default.
- W4362231427 countsByYear W43622314272020 @default.
- W4362231427 countsByYear W43622314272021 @default.
- W4362231427 countsByYear W43622314272023 @default.
- W4362231427 crossrefType "journal-article" @default.
- W4362231427 hasAuthorship W4362231427A5000513493 @default.
- W4362231427 hasAuthorship W4362231427A5008912538 @default.
- W4362231427 hasAuthorship W4362231427A5047279072 @default.
- W4362231427 hasAuthorship W4362231427A5070498394 @default.
- W4362231427 hasAuthorship W4362231427A5075222976 @default.
- W4362231427 hasConcept C104317684 @default.
- W4362231427 hasConcept C121608353 @default.
- W4362231427 hasConcept C126322002 @default.
- W4362231427 hasConcept C143998085 @default.
- W4362231427 hasConcept C146357865 @default.
- W4362231427 hasConcept C151730666 @default.
- W4362231427 hasConcept C185592680 @default.
- W4362231427 hasConcept C2776694085 @default.
- W4362231427 hasConcept C2776938808 @default.
- W4362231427 hasConcept C2777863537 @default.
- W4362231427 hasConcept C2778074268 @default.
- W4362231427 hasConcept C2779122487 @default.
- W4362231427 hasConcept C2911180711 @default.
- W4362231427 hasConcept C3018227240 @default.
- W4362231427 hasConcept C530470458 @default.
- W4362231427 hasConcept C55493867 @default.
- W4362231427 hasConcept C71924100 @default.
- W4362231427 hasConcept C86803240 @default.
- W4362231427 hasConceptScore W4362231427C104317684 @default.
- W4362231427 hasConceptScore W4362231427C121608353 @default.
- W4362231427 hasConceptScore W4362231427C126322002 @default.
- W4362231427 hasConceptScore W4362231427C143998085 @default.
- W4362231427 hasConceptScore W4362231427C146357865 @default.
- W4362231427 hasConceptScore W4362231427C151730666 @default.
- W4362231427 hasConceptScore W4362231427C185592680 @default.
- W4362231427 hasConceptScore W4362231427C2776694085 @default.
- W4362231427 hasConceptScore W4362231427C2776938808 @default.
- W4362231427 hasConceptScore W4362231427C2777863537 @default.
- W4362231427 hasConceptScore W4362231427C2778074268 @default.
- W4362231427 hasConceptScore W4362231427C2779122487 @default.
- W4362231427 hasConceptScore W4362231427C2911180711 @default.
- W4362231427 hasConceptScore W4362231427C3018227240 @default.
- W4362231427 hasConceptScore W4362231427C530470458 @default.
- W4362231427 hasConceptScore W4362231427C55493867 @default.
- W4362231427 hasConceptScore W4362231427C71924100 @default.
- W4362231427 hasConceptScore W4362231427C86803240 @default.
- W4362231427 hasIssue "4" @default.
- W4362231427 hasLocation W43622314271 @default.
- W4362231427 hasOpenAccess W4362231427 @default.
- W4362231427 hasPrimaryLocation W43622314271 @default.